OPEN BOARD AGENDA NEW JERSEY STATE BOARD OF MEDICAL EXAMINERS

October 8, 2014 PAGE - I

ROLL CALL

STATEMENT CONCERNING THE ANNUAL NOTICE OF PUBLIC MEETINGS

ANNOUNCEMENTS

MINUTES Approval of the August 13, 2014 Open Board

Minutes

Approval of the September 10, 2014 Open Board

Minutes

Approval of the June 17, 2014 Physician Assistant

Advisory Committee Open Minutes

NEW BUSINESS

Legislation

A3712 - Seeks to require health care practitioners to inform patients of addition potential of controlled dangerous substances prior to issuing prescription.

OPEN BOARD AGENDA NEW JERSEY STATE BOARD OF MEDICAL EXAMINERS

October 8, 2014 PAGE - 2

\$2366 - Seeks to require health care practitioners to inform patients of addiction potential of controlled dangerous substances prior to issuing prescription.

\$2378 - Seeks to extend the "Overdose Prevention Act" immunity provisions to certain professionals and professional entities, and requires needle exchange programs to obtain standing order for opioid antidote dispensation, appropriates \$500,000.

A3737 - Seeks to require insurers to provide minimum of 30 days inpatient treatment for substance abuse when physician determines treatment is medically necessary.

A3715 - Seeks to direct poison control and drug information program to establish clearinghouse of drug overdose information, report on trends, and provide education on safe storage and disposal of medications; appropriates \$500,000.

OLD BUSINESS

N.J.A.C. 13:35-7.1, 7.1A and 7.2 - Adoption Notice

The Board proposed amendments to the above noted regulations, Definitions, Examination of patient's condition required prior to dispensing drugs or issuing a prescription; exceptions; Requirements for issuing written prescriptions for medicines for notice and comment. The Comment period ended September 5,

OPEN BOARD AGENDA NEW JERSEY STATE BOARD OF MEDICAL EXAMINERS October 8, 2014 PAGE - 3

2014. Two comments from the following individuals: Melinda R. Martinson, General Counsel, Medical Society of New Jersey and Ryan D. White, MS, MPH, PA-C, Immediate Past President, Chair, Government Affairs Committee, New Jersey State Society of Physician Assistants. Attached for the Board's consideration are responses to the comments received. The Board is requested to publish it in the *New Jersey Register* as a Final Adoption.

INFORMATIONAL

A recent Federal Drug Enforcement Agency (DEA) Final Rule reschedules hydrocodone combination products (HCPs) from a Schedule III Controlled Dangerous Substance (CDS) to a Schedule II CDS on October 6, 2014. The Drug Control Unit has developed a general guidance document, which is attached, for both practitioners and pharmacies. It outlines the impact and limitations of HCPs when they become a Schedule II CDS on October 6, 2014.

PUBLIC COMMENT